Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Thursday, November 17th. The shares were sold at an average price of $52.15, for a total value of $521,500.00. Following the completion of the transaction, the chief executive officer now directly owns 587,177 shares of the company’s stock, valued at $30,621,280.55. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Halozyme Therapeutics Trading Up 0.3 %
Shares of HALO opened at $52.94 on Friday. Halozyme Therapeutics, Inc. has a 52-week low of $31.36 and a 52-week high of $54.88. The business’s fifty day moving average is $44.76 and its 200-day moving average is $44.72. The company has a debt-to-equity ratio of 15.37, a quick ratio of 5.03 and a current ratio of 5.97. The firm has a market cap of $7.16 billion, a price-to-earnings ratio of 35.53, a PEG ratio of 0.84 and a beta of 1.22.
Analyst Upgrades and Downgrades
Several equities analysts have weighed in on the company. Morgan Stanley assumed coverage on Halozyme Therapeutics in a report on Friday, September 9th. They issued an “overweight” rating and a $50.00 price objective for the company. JMP Securities lifted their price objective on Halozyme Therapeutics from $60.00 to $62.00 and gave the company a “market outperform” rating in a report on Wednesday, November 9th. StockNews.com initiated coverage on Halozyme Therapeutics in a research note on Wednesday, October 12th. They issued a “hold” rating on the stock. Finally, SVB Leerink lifted their price target on Halozyme Therapeutics from $52.00 to $62.00 and gave the company an “outperform” rating in a research note on Monday, November 14th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $54.57.
Institutional Investors Weigh In On Halozyme Therapeutics
About Halozyme Therapeutics
Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
- Get a free copy of the StockNews.com research report on Halozyme Therapeutics (HALO)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.